Santen Pharmaceutical Co Ltd
TSE:4536

Watchlist Manager
Santen Pharmaceutical Co Ltd Logo
Santen Pharmaceutical Co Ltd
TSE:4536
Watchlist
Price: 1 565.5 JPY -1.85% Market Closed
Market Cap: 543.3B JPY
Have any thoughts about
Santen Pharmaceutical Co Ltd?
Write Note
Santen Pharmaceutical Co Ltd
/
Balance Sheet
/
Additional Paid In Capital

Santen Pharmaceutical Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Santen Pharmaceutical Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Santen Pharmaceutical Co Ltd
TSE:4536
Additional Paid In Capital
¥9.4B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
2%
Takeda Pharmaceutical Co Ltd
TSE:4502
Additional Paid In Capital
¥1.7T
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
41%
Daiichi Sankyo Co Ltd
TSE:4568
Additional Paid In Capital
¥4B
CAGR 3-Years
N/A
CAGR 5-Years
-47%
CAGR 10-Years
-28%
Otsuka Holdings Co Ltd
TSE:4578
Additional Paid In Capital
¥504.5B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Chugai Pharmaceutical Co Ltd
TSE:4519
Additional Paid In Capital
¥69.5B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
0%
Astellas Pharma Inc
TSE:4503
Additional Paid In Capital
¥183.5B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
0%
No Stocks Found

Santen Pharmaceutical Co Ltd
Glance View

Market Cap
546.6B JPY
Industry
Pharmaceuticals

Santen Pharmaceutical Co., Ltd., a cornerstone of Japan's robust pharmaceutical industry, has been relentlessly focused on improving eye health worldwide. Founded in 1890, the company began as a modest medicine retailer in Osaka, but over the decades, it has skillfully navigated the evolving healthcare landscape to become a global leader in ophthalmology. Today, Santen's enterprise is intricately woven with innovation and specialization, stretching its influence far beyond its Japanese roots. Its main thrust lies in the research, development, and commercialization of ophthalmic products tackling a comprehensive range of eye disorders, from dry eyes to age-related macular degeneration and glaucoma. By investing significantly in R&D, Santen maintains a robust pipeline of new treatments that continuously feeds into its growing portfolio, ensuring its offerings are at the forefront of medical advancements. Santen's business strategy thrives on leveraging its scientific expertise to not only create but also efficiently bring products to market across various continents. It operates through a well-crafted distribution network that spans Asia, Europe, and North America, tailoring its marketing and regulatory approaches to suit regional healthcare environments. This global footprint allows Santen to capture diverse markets, each with unique demands, thereby enhancing revenue streams. The firm's operational model also includes strategic partnerships and acquisitions, enhancing its research capabilities and expanding its market share to sustain profitability. Santen generates revenue primarily through the sale of innovative ophthalmic prescription drugs and over-the-counter products, supported by its strong relationships with healthcare professionals and continued expansion into emerging markets. The company’s focused strategy and commitment to eye health solutions position it as an indispensable player in the global healthcare industry.

Intrinsic Value
2 320.46 JPY
Undervaluation 33%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Santen Pharmaceutical Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
9.4B JPY

Based on the financial report for Sep 30, 2024, Santen Pharmaceutical Co Ltd's Additional Paid In Capital amounts to 9.4B JPY.

What is Santen Pharmaceutical Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
2%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Santen Pharmaceutical Co Ltd have been 2% over the past three years , 2% over the past five years , and 2% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.